fashion -WSS

fashion

author：comprehensive 2025-10-01 12:11:34 - browse：553

Apellis Pharmaceuticals said Tuesday that it had identified “internal structural variations” in a type of needle used by doctors to prepare syringes of its eye disease drug Syfovre as a possible cause of severe eye inflammation reported in patients receiving the treatment — but the company stopped short of definitively linking the needle to the cases.

Additionally, Apellis confirmed one additional case of the severe and potentially blinding side effect, known as retinal occlusive vasculitis, or ROV, that occurred in May. But with thousands of more Syfovre eye injections also performed, the overall frequency of ROV remains unchanged and rare, even with the added scrutiny and increased physician monitoring.

Apellis shares rose 30% to $40 in Wednesday’s pre-market trading on the growing belief amongst investors that Syfovre’s safety crisis is abating.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： In age of alternative facts, a scholarly course on calling out crap
Next article： Merck drug for rare lung condition set for approval in U.S.

hotspot

WSS

Swim instructor mom warns parents not to buy blue swimsuits for kids

Judge agrees to delay next hearing in Trump classified documents case

Scientists boost immune system in aging mice by making it youthful

Eisai exec who led development of Alzheimer’s drug to retire

Home health providers sue Medicare over payment cuts

Covid vaccine financial winners and losers, from Pfizer to Novavax

Wikipedia

fashion

focus

United colonoscopy coverage change 'may cost lives,' doctors say

‘Insidious 5’ topples 'Indiana Jones' before ‘Mission: Impossible’ launches

Virginia high school admissions case could be legal follow

Biden targets hefty hospital 'facility fees' that often surprise patients

BioMarin wins approval for gene therapy to treat hemophilia A

Rikers Island jail violence not addressed, NYC should be held in contempt: Fed monitor

As demand for Covid shots wanes, Moderna seeks its next success

Accuser who called Kevin Spacey 'vile sexual predator' admits he joked about incident

Supreme Court strikes down use of affirmative action

Scientists boost immune system in aging mice by making it youthful

focus

The Readout: Lenmeldy, GLP

Supreme Court mifepristone arguments center on docs' right to sue

Merck drug for rare lung condition set for approval in U.S.

Donor acceptance rates hint at racial, gender bias in heart transplants: study

ACA's risk program benefits Blue Cross Blue Shield insurers

FDA's naming rule on biosimilars has undermined competition

focus

hotspot

entertainment

knowledge